Skip to main content
TipRanks
Go Ultimate75% OFF

Bristol-Myers Squibb (BMY) Revenue by Segment

12,197 Followers

Revenue by Segment

Bristol-Myers Squibb reported revenue by segment of $13.07B in Q3 2026, up 0.7% from Q2 2026 and up 6.9% year over year. This is the highest value since 2019.

Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.

$0.00$2.50B$5.00B$7.50B$10.00B$12.50BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product revenue has shifted from steady to accelerating in H1‑2026, reflecting the Eliquis-led and broader growth‑portfolio strength that underpins management’s raised guidance; this makes product performance the primary driver of near‑term upside. “Other” has become a noticeably lumpier but slightly larger contributor since late‑2024, adding volatility rather than scale, while Alliance receipts are flat-to-declining, signaling limited partner upside. The stock’s path now hinges on sustaining Eliquis/growth product momentum and successful launches—legacy generic pressure and Opdivo softness remain the main downside risks.

BMY Revenue by Segment

PeriodOtherProductAllianceTotal
Q3 2026Sep 30, 2026$368.00M$12.61B$95.00M$13.07B
Q2 2026Jun 30, 2026$281.00M$12.59B$104.00M$12.97B
Q1 2026Mar 31, 2026$227.00M$11.17B$94.00M$11.49B
Q4 2025Dec 31, 2025$277.00M$12.11B$115.00M$12.50B
Q3 2025Sep 30, 2025$247.00M$11.85B$125.00M$12.22B
Q2 2025Jun 30, 2025$241.00M$11.91B$119.00M$12.27B
Q1 2025Mar 31, 2025$227.00M$10.89B$88.00M$11.20B
Q4 2024Dec 31, 2024$407.00M$11.81B$124.00M$12.34B
Q3 2024Sep 30, 2024$304.00M$11.48B$105.00M$11.89B
Q2 2024Jun 30, 2024$160.00M$11.93B$116.00M$12.20B
Q1 2024Mar 31, 2024$172.00M$11.56B$134.00M$11.87B
Q4 2023Dec 31, 2023$162.00M$11.17B$147.00M$11.48B
Q3 2023Sep 30, 2023$183.00M$10.64B$138.00M$10.97B
Q2 2023Jun 30, 2023$130.00M$10.92B$179.00M$11.23B
Q1 2023Mar 31, 2023$145.00M$11.05B$144.00M$11.34B
Q4 2022Dec 31, 2022$159.00M$11.06B$182.00M$11.41B
Q3 2022Sep 30, 2022$232.00M$10.81B$173.00M$11.22B
Q2 2022Jun 30, 2022$203.00M$11.48B$199.00M$11.89B
Q1 2022Mar 31, 2022$152.00M$11.31B$188.00M$11.65B
Q4 2021Dec 31, 2021$155.00M$11.61B$221.00M$11.98B
Q3 2021Sep 30, 2021$187.00M$11.24B$194.00M$11.62B
Q2 2021Jun 30, 2021$139.00M$11.40B$159.00M$11.70B
Q1 2021Mar 31, 2021$133.00M$10.80B$142.00M$11.07B
Q4 2020Dec 31, 2020$139.00M$10.77B$163.00M$11.07B
Q3 2020Sep 30, 2020$159.00M$10.20B$184.00M$10.54B
Q2 2020Jun 30, 2020$149.00M$9.82B$163.00M$10.13B
Q1 2020Mar 31, 2020$135.00M$10.54B$105.00M$10.78B
Q4 2019Dec 31, 2019$104.00M$7.66B$179.00M$7.95B
Q3 2019Sep 30, 2019$96.00M$5.77B$143.00M$6.01B
Q2 2019Jun 30, 2019$96.00M$6.03B$146.00M$6.27B
Q1 2019Mar 31, 2019$78.00M$5.71B$129.00M$5.92B

Related KPIs